Varenicline Nasal Spray ( DrugBank: Varenicline )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 53 | シェーグレン症候群 | 1 |
53. シェーグレン症候群
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05700422 (ClinicalTrials.gov) | February 2023 | 14/1/2023 | Nasal Spray Study in Sjogren's Dry Eye Disease | A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome | Sjogren's Syndrome;Dry Eye | Drug: Varenicline Nasal Spray | University of Pennsylvania | Oyster Point Pharma, Inc. | Not yet recruiting | 18 Years | N/A | All | 40 | Phase 4 | NULL |